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Nightshift working is associated with sleep deprivation, fatigue and attention/
concentration deficits which, in healthcare workers, may impact on patient safety.
Clinical staff in the UK routinely work several 12 h nightshifts in a row at about 1–3
month intervals. We investigated the feasibility and acceptability of a crossover trial of
melatonin administration in clinical staff working nightshifts with an exploration of effects on
sleep measures and attention/concentration tasks. This was a pilot, double-blinded,
randomized, placebo-controlled crossover feasibility trial in doctors and nurses working 3
consecutive nightshifts at a tertiary referral hospital in the UK. Twenty five male and female
subjects were randomized to receive either 6mg Circadin™ slow release melatonin or
placebo before sleep after each consecutive nightshift, followed by a washout period,
before crossing over to the other experimental arm. We used actigraphy for objective
assessment of sleep parameters. The trial design was feasible and acceptable to
participants with negligible side effects, but elevated melatonin levels were prolonged
during the active arm (P=0.016). Double digit addition testing, a concentration/attention
task, improved with melatonin treatment (P<0.0001). Lapses of vigilance or judgement
while doctors or nurses are working nightshifts could impact on patient safety and
melatonin may be a useful intervention. This study supports the conclusion that a larger
definitive trial of this design is both feasible and safe.
Clinical Trial Registration: identifier ISRCTN15529655. https://www.isrctn.com/
Keywords: melatonin, randomized controlled trial, shift work, sleep, healthcare workersINTRODUCTION
Healthcare workers are reported to typically sleep only 4–7 h between nightshifts, associated with
sleep deprivation, fatigue, and performance deficit (1–4). There are increased risks of myocardial
infarction (5), type II diabetes (2), and rheumatoid arthritis (6) and there are also more occupational
injuries during nightshift working (7, 8).g August 2020 | Volume 11 | Article 8721
Thottakam et al. The MIDNIGHT TrialJunior doctors in the UK routinely work three or four 12 h
nightshifts at intervals of around 1–3 months and nurses may
work up to 7 nightshifts in a row. Similar patterns of either 8 h or
12 h are common in hospitals in the USA (9, 10) and elsewhere
in Europe (3) but nightshifts can last up to 16 h in Japan (11).
Lapses of vigilance or judgement due to sleep deprivation
while clinical staff are working nightshifts could impact on
patient safety. So-called jet lag has similar effects to shift
working and systematic reviews suggest there is evidence to
support the use of melatonin. The only licensed form of
melatonin in the UK is Circadin™, a modified release
formulation, licensed for treating primary insomnia in older
adults. The feasibility, safety and acceptability of its use for
clinical staff working nightshifts is not known. We therefore
undertook a pilot, double-blinded, randomized, placebo-
controlled, 2x2 crossover feasibility trial of Circadin in doctors
and nurses working real life nightshifts at a tertiary referral
hospital in the UK. We also undertook an initial exploration of
efficacy in terms of sleep parameters and effects on concentration
and attention tasks, to inform a subsequent definitive trial.METHODS
The Medicines and Healthcare Regulatory Authority (MHRA)
ruled that this was not a Clinical Trial of an Investigational
Product (CTIMP) and a Clinical Trial Authorization was
therefore not required. Following ethical committee (North of
Scotland Research Ethics Service, reference 16/NS/0010) and
NHS Grampian management (reference 2016AN001) approvals,
expressions of interest in taking part in the study were invited via
emails sent to all acute care nurses and trainee doctors
throughout NHS Grampian, which comprises Aberdeen Royal
Infirmary, Royal Aberdeen Children’s Hospital and Aberdeen
Maternity Hospital, plus outlying hospitals. Any doctor or nurse
who worked 12 h shifts of at least 3 nights in a row was
potentially eligible, as long as they worked during the entire
shift with no opportunity to nap, and each set of shifts was about
a month apart. Shift start times were 19:30 or 20:00 and were of
12 h duration for all subjects. Nobody finished earlier and
nobody worked more than 15 min longer.
Subjects were excluded if they were pregnant or breastfeeding,
had a pre-existing chronic health condition and/or took any
regular medication other than oral contraceptives, had a body
mass index (BMI) of more than 30 Kg/m2 or were smokers. To
reduce the possibility of recruiting any female participant who
may become pregnant, all women were asked confirm they were
either on reliable contraception, had been sterilized, were post-
menopausal or declared themselves to be sexually inactive, and
so were not likely to become pregnant.
Confirmation of participants’ eligibility and clinical oversight
was provided by Dr Allen and ProfessorWebster, both Consultants
in Intensive Care Medicine. The study was monitored by NHS
Grampian and a Data and Safety Monitoring Committee was
appointed. After written informed consent, subjects were randomizedFrontiers in Psychiatry | www.frontiersin.org 2to receive either 6mg Circadin™ (Flynn Pharmaceuticals Ltd.) or
a placebo of identical appearance, before sleep during their first
series of three shifts and the opposite for the second series of three
shifts. The randomization schedule was provided to the Clinical
Trials Pharmacy in advance by an independent statistician not
involved in the trial, in blocks of 8 to further minimize any
seasonal effects. Circadin is a modified release formulation with a
blood concentration profile resembling that of endogenous
melatonin. Both Circadin and the placebo were provided by
Flynn Pharma and were repackaged, labeled and dispensed by
the Clinical Trials Pharmacy at Aberdeen Royal Infirmary who
were also responsible for drug accountability. The study was
sponsored jointly by the University of Aberdeen and NHS
Grampian. Flynn Pharma had no input to study design
or conduct.
The trial design is summarized in Figure 1. Subjects were
allowed to familiarize themselves with the various tasks
beforehand. Subjects completed the Composite Score of
Morningness (CSM) (12) and, immediately before the first
night shift they completed the Verran Snyder Halpern (VSH)
sleep scale, a validated assessment tool which uses 100mm visual
analogue scales to record self-reported sleep disturbance,
efficiency and supplementation in the previous 24 h period
(13). A psychomotor vigilance task (PVT) was undertaken on
a laptop computer with a Razer Abyssuss™ high performance
gaming mouse (Amazon.co.uk). The test requires sustained
attention and measures reaction time to a visual stimulus (14).
Subjects also completed a timed double-digit addition task
(DDAT) where a random sheet from 25 different sheets of 20
double-digit sums was provided and subjects were given 30 s to
complete as many as possible as accurately as possible (15). No
subject received the same DDAT sheet more than once. Finally,
subjects completed the Epworth Sleepiness Scale (ESS), which
records self-reported situational propensity to fall asleep (16).
Blood samples were taken before and after shifts (see below).
During the nightshift subjects worked all night and were not able
to nap. They were sent automated text messages at 04:00 to
remind them to complete the ESS at that time.
The following morning, immediately after the shift,
participants completed the PVT, DDAT, VSH and ESS
assessments again. They were given nine x 2 mg Circadin or
placebo tablets and asked to take 3 tablets (6 mg) with a snack at
home after each shift, and to go to bed within 2h of taking the
tablets. The time of taking the tablets and the time of going to
bed/getting up were self-reported. Subjects wore sunglasses on
the way home to minimize light exposure and were given an
Actiwatch™ (Phillips Spectrum PRO, Linton Instrumentation
Ltd., Diss, Norfolk, UK) to wear. Actiware™ software (Philips
Respironics, V6.0) enables analysis, management and export of
objective activity data, providing times of going to bed and
getting up, duration of time in bed, time actually asleep, sleep
latency, and minutes awake after sleep onset (WASO); it concurs
with polysomnography (17). Participants only wore the
Actiwatch at home as watches cannot be worn during clinical
time. We asked participants after every shift about napping; all
staff reported that they had not napped. At the start of the nextAugust 2020 | Volume 11 | Article 872
Thottakam et al. The MIDNIGHT Trialshift all measures were repeated and the Actiwatch data downloaded.
On the fourth evening final assessments were undertaken and the
medication bottle was collected. Participants were asked daily about
adverse effects and were given a post-participation questionnaire
which they completed anonymously and returned in a sealed
envelope; these were not opened until recruitment was complete.
Biochemical Assays
Blood samples were collected into clot activator tubes and
centrifuged within 2 h of collection for 10 min at 2,300g and
the serum stored at -80°C. Melatonin was measured using liquid
chromatography-tandem mass spectrometry, reported in fullFrontiers in Psychiatry | www.frontiersin.org 3elsewhere (18). The assay monitors levels after exogenous
melatonin administration with a lower limit of quantification
of 50 pg/ml. Blinding was maintained throughout. Biochemistry
(urea and electrolytes and liver function tests) and hematology
(full differential leukocyte counts and hemoglobin) tests were
undertaken using standard methods in our hospital laboratories.
Statistical Analysis
The primary aim of this pilot study was feasibility and
acceptability of the trial design, and safety, with an exploration
of effectiveness in a real-life situation. Our primary outcome
measure was 25 subjects completing both cross-over arms; thisFIGURE 1 | Trial visit summary. ESS, Epworth sleepiness score; CSM, composite scale of morningness; DDAT, double digit addition task; PVT, psychomotor
vigilance task; VSH, Verran-Snyder-Halpern sleep scale.August 2020 | Volume 11 | Article 872
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crossover design. Secondary aims were to assess melatonin levels
and to explore effects of melatonin and nightshifts on sleep
measures and attention/concentration tasks. Data are presented
as median and full range and were analyzed using mixed models
with maximum likelihood estimation for repeated measures in a
crossover design. This included tests for treatment (melatonin),
period and treatment by period interactions (sequence or
carryover effects). Bonferroni multiple comparison corrections
were applied to keep the overall type 1 error rate at <5%. Non-
parametric analysis was used as appropriate. Significance was
defined as P<0.05 (two-sided). Analyses were conducted using
Number Cruncher Statistical Systems 12 (NCSS), NCSS Inc.,
Kaysville, UT, USA, StatXact 9, Cytel Inc., Cambridge, MA, USA
and StatsDirect 3, StatsDirect Ltd., Cambridge, UK.RESULTS
Recruitment, Feasibility, and Participant
Feedback
Crossover trials are renowned for higher attrition rates than
other trial designs. We therefore allowed for 30% dropout, and
aimed to recruit 32 subjects to achieve our primary outcome
measure of 25 subjects completing both crossover arms. However
our dropout rate was lower than anticipated such that this was
achieved after recruiting 30 subjects. The CONSORT flow
diagram in Figure 2 shows recruitment data. There were 104
initial expressions of interest but 40 people did not respond after
receiving further information. Three people declined to take part.
Ten subjects were ineligible, due to smoking, BMI>30 Kg/m2 or
chronic medication use. Twenty-one subjects were eligible but
unable to take part due to incompatibility of shift patterns or
dates, or geographical location. Two subjects were withdrawn after
consent but before randomization, as they were subsequently
found to meet the exclusion criteria. Three more withdrew after
randomization, one for personal reasons, one due to acute ill-
health unrelated to the trial, and one left the geographical area.
The median [range] duration between each shift series (=periods)
was similar between those who had placebo and those who had
melatonin first (6.7 [3.6–14.4] and 7.7 [3.9–13.0] weeks,
respectively, P=0.43, Table 1).
The characteristics of subjects and CSM scores for each
randomized sequence were similar (Table 1). All subjects
completed all scheduled tasks and there were no protocol
violations, no serious adverse events and very few adverse events.
Three subjects reported headaches, revealed later to be one during
the placebo arm and 2 during the melatonin arm, although one of
the latter had not yet taken any melatonin. Two people reported
“strange” dreams, one during placebo and one during melatonin.
One person reported being “excessively drowsy” after taking trial
medication (later revealed to be melatonin).
Anonymous post-trial surveys were returned by 24/25 (96%)
participants (Table 2). Five-point Likert scales (strongly agree/
agree/ambivalent/disagree/strongly disagree) recorded responsesFrontiers in Psychiatry | www.frontiersin.org 4to statements. The final question asked if subjects would take
melatonin when working nightshifts if it was available (Table 2).
Overall, 88% strongly agreed/agreed that the trial was well
organized and 100% strongly agreed/agreed that communication
was good. Overall 54% strongly disagreed/disagreed that they
were inconvenienced by taking part, 5 (20%) people were
ambivalent and just one person felt inconvenienced. Eleven
(46%) agreed/strongly agreed they would take melatonin if it
were available, 12 (50%) were unsure if they would or not and one
person said they would not take it.
Blood Analyses
There were no differences in hematology and biochemical data at
baseline and although there were some statistically significant
changes over the course of the study, these were considered to be
clinically irrelevant (Supplementary Table S1).
Serum melatonin concentrations were below the lower limit
of quantification (50pg/ml) in all samples during placebo shifts
and in all baseline samples (i.e., before the first shift for both
treatment arms). Figure 3 shows serum melatonin levels after
each shift during the melatonin treatment periods only. Melatonin
levels were very variable between individuals such that some
participants had circulating melatonin levels below the lower
limit of detection during the melatonin treatment period while
others had very high levels. There was a significant effect of shift on
melatonin levels (P=0.01) and levels were significantly higher after
shift 3 than shift 2 (P=0.016). No unused tablets were returned.
Sleep
ESS is a self-reported score assessing situational propensity for
dozing or “sleepiness”. There was pronounced variation between
participants but it is clear that ESS was lower before every shift
than during and after each shift during both placebo and
melatonin treatment arms (both P<0.0001 overall, Figure 4A).
There was also a shift effect (P=0.0026) such that that ESS was
lower throughout shift 3 than shifts 1 and 2 during both
treatment periods (Figure 4B). In addition, overall there was a
significant treatment effect with increased ESS during melatonin
treatment due to higher ESS scores overall during shift 2
(p=0.0072, Figure 4B).
Sleep latency, duration and WASO were assessed objectively
using Actigraphy, and subjective sleep disturbance and efficiency
were assessed using the VSH scale (Table 3). Latency (the time
taken to fall asleep) was variable but in all cases less than 16mins
and was not affected by nightshift working. There were no
significant effects of treatment found. Sleep duration was a
median of 5–6 h but some participants slept for as little as 2 h
and some as long as 8h. Duration of sleep decreased over the shift
series in both treatment periods (P<0.0001, Table 3) with over an
hour less sleep after shift 3 than after shift 1. However no
significant effects of melatonin treatment were seen. The
amount of time participants spent awake after going to sleep
(WASO) was a median of about 30 min and decreased by 10 min
over both shift series (P=0.012 Table 3).
The maximum possible score for sleep disturbance recorded
using the VSH scale is 700; a lower score indicates lessAugust 2020 | Volume 11 | Article 872
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participants were higher than we found previously in healthy
young men (18). Disturbance score decreased over the shifts
(P=0.031) and was most marked after shift 3 during melatonin
treatment although this did not reach significance (Table 3).
Sleep efficiency recorded using the VSH scale has a maximum
score of 500; values here were similar to what we have seen in
healthy young men (18) (Table 3).
Concentration and Attention Tasks
Concentration and attention was assessed by double digit
addition and reaction time testing. The range of the number ofFrontiers in Psychiatry | www.frontiersin.org 5sums correctly answered in the DDAT test varied from 2 to 16.
There was an increase in the number correct over both series of
shifts (P<0.0001 overall, Figure 5A) and scores were higher
during melatonin treatment (P<0.0001, Figure 5B). There were
no differences between males and females.
Reaction times varied between 200 and 400 ms and male
participants had significantly faster PVT reaction times than
females at baseline, before the first shift (P<0.006, Figure 6A).
Reaction times were slower after shifts than before in both sexes
(P=0.0007, Figures 6B, C). There were very few PVT lapses
(>500 ms, data not shown) and no significant difference between
melatonin and placebo treatment periods was seen.FIGURE 2 | CONSORT diagram.August 2020 | Volume 11 | Article 872
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Frontiers in Psychiatry | www.frontiersin.org 6DISCUSSION
We report here that this rigorous pilot Phase II feasibility trial of
Circadin compared to placebo in doctors and nurses working
real life nightshifts was feasible, safe, and acceptable to
participants. All subjects completed both arms of the study
with no protocol violations. There were negligible side-effects
with no wellbeing or safety concerns, and compliance with the
protocol was excellent. Although this was a pilot study and any
effects seen were secondary outcome measures, working
nightshifts significantly affected sleep disturbance, duration,
and time spent awake after sleep onset and subjective
sleepiness was poorer during shifts. Circulating melatonin
levels were very variable between individuals and were
undetectable in some but remained high in other subjects
during Circadin treatment even 8 h after taking the tablets.
Attention and concentration tasks were significantly impacted by
nightshift working and we found some differences between males
and females. Melatonin treatment was associated with improved
double-digit addition task scores.
Previous studies have shown that working nightshifts impacts
on health generally and on functional performance during the
shift itself, both in simulation studies and real-life workers (1,
2, 5, 19, 20). Here we show the study design for a trial of
administration of melatonin was feasible and acceptable to
participants in real-life working situations for clinical staff in a
hospital environment. The intervention was well tolerated and
not associated with adverse events, thus raising no safety
concerns. We found no differences between those receiving
melatonin first and those receiving placebo first. Although
there was a possibility that giving melatonin during nightshift
working to help daytime sleep may have meant there were issuesFIGURE 3 | Serum melatonin concentrations at baseline and after each shift during the melatonin arm (n = 25). Levels increased significantly over the series of shifts
(P = 0.01 overall) and were higher after shift 3 than shift 2 (P = 0.016). Melatonin levels were not detectable at baseline in any participant. Box and whisker plots





The trial was well organised 21 3 0
Communication was good 24 0 0
Taking part was not too
onerous
19 4 1
There were too many tasks 3 3 18
There were too many blood
samples
8 8 8






I had side effects from taking
part
1 3 20
I would take melatonin if it
was available
11 12 1
I think I know if I had
melatonin or placebo first





Age (years) 28 [24–56] 27 [24–56]
Sex (male:female) 4:9 4:8
BMI (kg m-2) 24.3 [18.1–30.0] 23.0 [19.3–27.3]
CSM score 31 [20–44] 42 [23–50]
Weeks between treatment arms 6.7 [3.6–14.4] 7.7 [3.9–13.0]Data are median [full range].
BMI, body mass index; CSM, composite scale of morningness.August 2020 | Volume 11 | Article 872
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Measure Treatment arm/shift Analysis
Placebo Melatonin Shift Treatment











































































P=0.066 P=0.85Frontiers in Psychiatry | www.frontiersin.org August 207 20 | Volume 11 |Median [full range]. WASO, wake after sleep onset. The median values are in bold.A
B
FIGURE 4 | (A) Epworth sleepiness score before, during and after each series of shifts. ESS was significantly lower before than during and after each shift
(P<0.0001 overall) and higher after the shift than during the shift (P = 0.0045 overall). *significantly lower than during or after shift, p<0.05. (B) Total Epworth
sleepiness score for each shift. Scores decreased significantly over the three shifts (P = 0.0026 overall). Box and whisker plots show median, interquartile, and full
range (n = 25).Article 872
Thottakam et al. The MIDNIGHT Trialon return to dayshifts, nothing was reported by any participant.
Notably, none of the participants who were randomized to
receive melatonin first reported sleep problems on return to
day shifts after the first shift series. However, we concede that
this was not the focus of our study and we did not formally assess
sleep after return to dayshift working. We did not restrict normal
activities, nor dictate participants’ sleeping habits prior to
starting night shifts, such as napping during the day, staying
up late, or all night. There was no restriction on exercise during
the study, or on caffeine/food intake or timing of daytime sleep,
although we did ban alcohol consumption in the 24 h before the
shifts and during the entirety of the two series of shifts. The
primary study aim was to determine feasibility and safety but
with robust multivariate cross-over analysis to comprehensively
explore any influence of nightshift working on sleep parameters
and attention/concentration tasks including analysis of the
impact of randomization sequence, shift, period (i.e., shiftFrontiers in Psychiatry | www.frontiersin.org 8series) and melatonin treatment to inform a subsequent
definitive trial. No previous studies have attempted to dissect
temporal effects which may compound interpretation of the
effectiveness of an intervention in this situation in this
participant population.
Crossover trial designs use longitudinal measurements which
minimize seasonal effects by randomizing to treatment
sequences. Confounding variables are reduced as each subject
acts as their own control. Crossover designs are statistically
efficient and require far fewer participants than other repeated
measures designs. As such, this design was appropriate here. The
main disadvantage of the design is carry-over. However we
allowed an adequate washout period between periods -this is
usually recommended to be 5 x the half-life of the drug. The
Summary of Product Characteristics for Circadin reports that the
time to maximum circulating levels in the non-fasted state after a
2 mg dose is around 3 h, with a half-life of approximately 4h andA
B
FIGURE 5 | (A) Double digit addition testing (DDAT) before and after each series of shifts. (B) Total number of correct answers in DDAT for each shift. Scores
increased significantly over the three shifts during both treatment arms (P < 0.0001 overall) and were higher during melatonin treatment (P < 0.0001 overall). Box and
whisker plots show median, interquartile, and full range (n = 25).August 2020 | Volume 11 | Article 872
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Frontiers in Psychiatry | www.frontiersin.org 9complete elimination by 12 h. Our median time between
treatment arms was around 7 weeks. In addition serum
melatonin was not detectable before each treatment arm in any
participant. Although cross-over designs often have a high
dropout rate due to participants being in the trial for longer
than other trial designs, this was not the case here, possibly due
to the participant demographic.
We have described the assay for melatonin previously (18);
slight adjustments were made to improve the lower limit of
quantification given the lower dose of melatonin used here. The
method is designed to analyze melatonin levels after exogenous
administration and is not sensitive enough to detect endogenous
levels; it was therefore unsurprising that melatonin was
undetectable in baseline samples or during placebo treatment.
Circadin is a modified release formulation of melatonin and we
found that circulating levels were highly variable during
treatment and in some cases undetectable in a few individuals,
yet markedly elevated in other individuals even 8–10 h after they
had taken Circadin. Most previous interventional studies do not
report melatonin levels and there is no consensus for an
appropriate dose. We and others have reported considerable
inter-individual variation in melatonin levels after administration
of immediate release melatonin (18, 21) thought to be due to
genetic polymorphisms of liver enzymes responsible for first pass
metabolism (22). We did find that prolonged elevation in
melatonin levels and possible accumulation seen here was not
associated with any functional deficit. The increasing levels over
the shifts during melatonin dosing suggests delayed clearance by
those with a slow metabolizing phenotype, and/or accumulation
due perhaps to the dose used. Circadin treatment appears to be
very safe with negligible side effects in this population of healthy
subjects, as we have reported previously using an immediate
release formulation, even at doses of 100mg (18). A recent trial
of 2 mg Circadin for 6 weeks for nocturia in patients with multiple
sclerosis reported more side effects during the placebo arm than
during melatonin but circulating melatonin levels were not
measured (23).
Previous studies investigating melatonin administration during
real-life shift working in healthcare workers have used various
doses of either immediate or modified release melatonin: 1mg
(24), 5 mg (25) or 6mg (26). All of these studies had a similar trial
design to our study and the intervention was given after the
nightshift, immediately before participants went to bed, i.e., in the
morning. Modified release Circadin is currently licensed in the EU
for treatment of primary insomnia at a dose of 2 mg. We chose to
use 6 mg Circadin since this dose had been shown to maximize
sleep-promoting effects while minimizing detrimental effects on
functional performance in military aircrew given a single dose
(27). Our previous work showed no concerning effects even after
100 mg of immediate release melatonin (18).
Nightshift working in our study affected sleep duration,
WASO and propensity for situational sleepiness measured
using ESS. Sleep duration determined by Actigraphy decreased
markedly across the shifts, regardless of treatment arm, and
indicates the complexity of disentangling the temporal effects of
shift work on sleep. What is of particular concern is that someA
B
C
FIGURE 6 | (A) Psychomotor vigilance testing (PVT) as reaction time in male
(n = 8) and female (n = 17) participants at baseline, before the first shift
regardless of treatment arm. Reaction times were significantly faster in males
than females at baseline (P = 0.006). (B) PVT tests before and after placebo
shifts and (C) PVT before and after melatonin shifts. Female participants’ data
points are shown in green and male participants’ in orange. Reaction times
were faster in males than females during all shifts. Reaction times were
significantly higher after shifts (P = 0.0007) in both males and females than
before. Box and whisker plots show median, interquartile, and full range with
individual raw data points overlaid.August 2020 | Volume 11 | Article 872
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busy clinical environment. We are aware that some participants
will have had domestic/caring duties to attend to which may have
compromised the amount of time available to them for daytime
sleeping after their shifts had ended. Sleep disturbance, measured
here using the VSH sleep scale, significantly improved during
each series of shifts, notably so after shift 3, and, although there
was no significant effect of Circadin overall, there was less sleep
disturbance after shift 3 during melatonin treatment. Actigraphy
is much more convenient compared to polysomnography but
periods of inactivity may be recognize as “sleep” such that latency
may be underestimated and duration overestimated (17).
However in a cross over trial in healthy subjects the impact of
this is minimal. Sleep latency (the time taken to fall asleep)
measured by Actigraphy, appeared faster after the first shift than
subsequent shifts, which may be expected given most subjects
had usually not slept for around 24 h at this point. We found no
significant effect of melatonin treatment on latency, in
concurrence with previous studies of real-life nightshifts using
immediate release melatonin (24–26). Studies in patients with
pre-existing sleep issues have reported variable effects of
melatonin on latency (23).
Self-reported sleepiness is acknowledged as a sensitive
indicator of insufficient sleep and both the ESS and other
similar scores are widely used (15, 25, 28–30). ESS has not
been specifically validated for changes in individuals over time,
but more sleepiness during and after shifts than before was very
apparent here, with some improvement by the third shift,
suggesting adaptation. No interventional study of real-life shift
working has reported sleepiness scores during shifts. We found a
small but statistically significant effect of melatonin treatment on
ESS during the second shift. The reason for this is not clear and this
did not impact on performance in attention/concentration tasks.
DDAT assesses attention and concentration, not working
memory or mathematical ability; the level is that of a child
aged around 8 years (31). It is said not to be affected by learning
although we found that scores improved over both series of shifts
perhaps suggesting otherwise, but with a significant treatment
effect on DDAT beyond any adaptation or practice effects. There
was no capacity for participants to learn the actual answers to the
sums as these were completely different each time. However the
technique of undertaking the sums can be learned much like a
child learning what to do to get the answer rather than learning
the actual answer to a particular sum. A previous study of ICU
nurses found adverse effects of nightshifts on mathematical
problem-solving (15). No other studies have investigated the
effect of melatonin treatment on DDAT.
The main finding in relation to PVT was pronounced
differences between male and female participants, which we
have noted previously in members of the public. It is worth
stating that binary assignment to “male” or “female” was assumed
based on participants’ names and appearance. Anecdotally PVT
has been reported to be ‘virtually unaffected’ by aptitude or
learning (14, 32), although more recent work disputes this (33).
PVT response is impaired in sleep-deprived medical interns (34)
but sex differences in performance were not reported. SomeFrontiers in Psychiatry | www.frontiersin.org 10studies have described sex differences (35, 36); some have
included only one sex, but most do not consider the effect of
sex at all. Reporting the sex of the participants in randomized
studies using PVT as a functional assessment is clearly important.
We found that PVT reaction times were worse after each shift
than before in all participants regardless of treatment arm.
In summary, fatigue and sleep deprivation which could result
in lapses of vigilance or judgement while doctors or nurses are
working nightshifts, might impact on patient safety; melatonin
administration may benefit sleep and functional performance
during nightshift working. This pilot study shows that
administration of melatonin as Circadin to clinical staff working
nightshifts is safe with no concerning side effects and the trial design
was feasible, and acceptable to participants, with no wellbeing
concerns raised. Only one person said they would not take
melatonin while working nightshifts if it was available. The
wearing of the actigraphy watch for objective assessment of sleep
parameters was well tolerated and did not interfere with normal
activity. No previous studies have undertaken such a comprehensive
and robust study of administration of melatonin during real-life
nightshift working to assess safety, feasibility and acceptability along
with an exploration of effects on sleep and functional capacity.
Other medications are available which may be of help to those
working nightshifts. Armodafinil and Modafinil are similar to
amphetamines and promote wakefulness through an unknown
mechanism. Armodafinil can be addictive with a number of
unpleasant side effects and Modafinil has drug interactions (for
example with cyclosporin, phenytoin and the contraceptive pill).
Ramelteon and tasimelteon are melatonin receptor agonists; the
former is licensed for sleep latency issues and the latter for non-
24 h sleep-wake disorder in blind individuals. Neither drug has
been tested in the context of nightshift working. Melatonin, in
comparison, is without concerning side effects.
Although there were some significant findings in our study
this was a pilot feasibility study and was designed to test the
feasibility and acceptability of the trial design. A type II error
(insufficient power) may mean that our inability to find an effect
may not necessarily mean there was no effect. A properly
powered definitive trial is the next step. We conclude that this
trial design for a larger definitive study is both feasible and safe.DATA AVAILABILITY STATEMENT
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